In the study, melatonin had further injury-reducing effects through decreased apoptotic cell death and lesion volume and a significant reduction in levels of expression of the Alzheimer’s disease marker proteins beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1), APP, and Aβ proteins. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.